Most importantly, these agents restored effector function to NK cells engaged in chronic interactions with autologous primary ovarian cancer cells, suggesting that TGF-β mediated immune evasion might be successfully blocked in vivo. This evidence concerns the gene TGFB1 and ovarian cancer.